ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

May 12, 2009 09:20 ET

Germany's Gottingen University Buys ART SoftScan Optical Breast Imaging System

University Medical Center Göttingen has also committed to purchase a second SoftScan system, fully upgraded for use in screening with molecular probes, subject to grant funding

MONTREAL, CANADA--(Marketwire - May 12, 2009) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that it has received a purchase order for one of its SoftScan® breast imaging systems from the Department of Radiology of the University Medical Center Gottingen, in Germany.

"We are very proud to see that the interdisciplinary molecular imaging group of the University of Gottingen, in cooperation with the Max-Planck-Institute of Experimental Medicine, has chosen our SoftScan breast imaging system to conduct world-class research in the field of translational oncology and radiology and to have them among our growing base of clients," said Sebastien Gignac, Chairman & CEO of ART. "The fact that the Interdisciplinary Imaging Group Gottingen, in which radiologists, oncologists, physicists, molecular biologists, imaging scientists and chemists work in close collaboration, has ordered a SoftScan system is testimony to the power of our technology to address the needs of leading researchers in the field of oncology," added Mr. Gignac.

The University Medical Center Gottingen Department of Diagnostic Radiology already owns an ART Optix® preclinical imaging system and plans on using the SoftScan system to further its development of cancer monitoring while exploring new therapies. In a second phase of the research, the Interdisciplinary Imaging Group Gottingen intends to use NIR (near-infrared) fluorescent biomarkers to monitor and treat specific cancers as well as identify metastatic propagation mechanisms. "We feel that ART's time domain technology will allow us to find novel imaging diagnostics for individual therapies to mark further advances towards a more personalized medicine in oncology," said Dr. Christoph Engelke, Department of Diagnostic Radiology, and Professor Frauke Alves, Department of Hematology and Oncology, University Medical Center Gottingen.

About the SoftScan® system

The SoftScan® optical breast imaging system has been designed first as a complementary diagnostic tool to mammography, with ultimate uses in the detection and treatment monitoring of breast cancer. Its non-invasive, painless approach uses time-domain optical imaging technology, which enables clinicians to better locate and characterize breast tumors as benign or malignant and could provide faster assessment of therapeutic effectiveness. Unlike mammography whose use must be strictly limited, the SoftScan system emits no radiation and can be safely used as often as needed to monitor patients. The device was created and developed by ART Advanced Research Technologies Inc., and has obtained market clearance for its commercialization in Canada and in Europe.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

About the University of Gottingen

Founded in 1737, the Georg-August University of Gottingen is a research university of international renown with strong focuses in research-led teaching. One of the largest national higher education institutions, it is officially rated amongst the nine German elite institutions of higher education. Gottingen combines an impressive number of analytical and biomedical research institutes and university faculties -including the University Medical Center Gottingen, three Max-Planck Institutes, the German Primate Center, the Gottingen Laser Institute and the European Neuroscience Institute-and has been linked with more Nobel Prizes than any other city in Europe, excluding Stockholm. This high science density provides a unique expertise and equipment landscape, and facilitates integrated multidisciplinary research. For more information, please visit the University of Gottingen web site at http://www.uni-goettingen.de/en.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in ART's most recent Annual Information Form and the financial statements for the year ended December 31, 2008, available on SEDAR (www.sedar.com).

Contact Information

  • ART Advanced Research Technologies Inc.
    Jacques Bedard
    Chief Financial Officer
    514-832-0777
    jbedard@art.ca
    or
    ART Advanced Research Technologies Inc.
    Mario Khayat
    Vice President, Optical Products
    514-832-0777
    mkhayat@art.ca
    www.art.ca